How to initiate fluid management for hyponatremia (low sodium levels) with a serum sodium level of 123 mEq/L (milliequivalents per liter)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a patient with hyponatremia and a sodium level of 123 mEq/L, the initial approach should be to restrict fluid intake to 1,000 mL/day and consider cessation of diuretics, as this is a case of moderate hyponatremia. The management strategy should prioritize the severity of symptoms and the underlying cause of hyponatremia. According to the guidelines by the American Association for the Study of Liver Diseases 1, water restriction to 1,000 mL/day and cessation of diuretics is recommended for moderate hyponatremia (120-125 mEq/L).

Key Considerations

  • The use of hypertonic saline is generally reserved for short-term treatment of patients with symptomatic or severe hyponatremia, or those with imminent liver transplant 1.
  • The goal rate of increase of serum sodium is 4-6 mEq/L per 24-hour period, not to exceed 8 mEq/L per 24-hour period to ameliorate the risk of osmotic demyelination syndrome 1.
  • For patients with severe symptoms, such as confusion, seizures, or coma, more aggressive correction with hypertonic saline may be necessary, with careful monitoring to avoid overly rapid correction 1.
  • Frequent monitoring of serum sodium levels is essential to adjust the treatment approach as needed.

Treatment Approach

  • For asymptomatic or mildly symptomatic patients, fluid restriction is often the first step, particularly if the patient is euvolemic or hypervolemic.
  • For hypovolemic hyponatremia, isotonic saline can be used until euvolemia is achieved.
  • Addressing the underlying cause of hyponatremia is crucial, which may include discontinuing offending medications, treating SIADH with fluid restriction or medications, or managing heart failure or cirrhosis appropriately.

From the FDA Drug Label

Patients were randomized to receive either placebo (N = 220) or tolvaptan (N = 223) at an initial oral dose of 15 mg once daily. The dose of tolvaptan could be increased at 24-hour intervals to 30 mg once daily, then to 60 mg once daily, until either the maximum dose of 60 mg or normonatremia (serum sodium >135 mEq/L) was reached

To start hyponatremia fluids for a sodium level of 123 mEq/L, the initial dose of tolvaptan is 15 mg once daily. The dose can be increased at 24-hour intervals to 30 mg once daily, then to 60 mg once daily, until either the maximum dose of 60 mg or normonatremia (serum sodium >135 mEq/L) is reached 2.

From the Research

Treatment of Hyponatremia

To start hyponatremia fluids for a sodium level of 123, the following options can be considered:

  • Isotonic saline for hypovolemic patients 3, 4
  • Fluid restriction for euvolemic patients 3, 4
  • Diuresis for hypervolemic patients 3
  • Hypertonic saline for severe symptomatic hyponatremia 3, 5, 4, 6
  • Vasopressin receptor antagonists (vaptans) for euvolemic and hypervolemic hyponatremia 5, 7

Classification of Hyponatremia

Hyponatremia can be classified based on volume status:

  • Hypovolemic: treated with isotonic saline 4
  • Euvolemic: treated with fluid restriction and/or vasopressin receptor antagonists 3, 4, 7
  • Hypervolemic: treated with diuresis and addressing the underlying cause 3, 4

Severe Hyponatremia

For severe hyponatremia (sodium ≤ 120 mmol/L), a bolus of 250 mL NaCl 3% may be more effective than 100 mL in rapidly increasing serum sodium levels 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Electrolytes: Sodium Disorders.

FP essentials, 2017

Research

[Treatment of hyponatremia: new developments and controversies].

Deutsche medizinische Wochenschrift (1946), 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.